LJI Wealth Management LLC Increases Stock Position in Kodiak Sciences Inc. (NASDAQ:KOD)

LJI Wealth Management LLC boosted its holdings in shares of Kodiak Sciences Inc. (NASDAQ:KOD) by 21.3% in the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 17,100 shares of the company’s stock after acquiring an additional 3,000 shares during the period. LJI Wealth Management LLC’s holdings in Kodiak Sciences were worth $45,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also bought and sold shares of the company. SG Americas Securities LLC purchased a new position in shares of Kodiak Sciences in the third quarter worth approximately $33,000. Meeder Asset Management Inc. bought a new stake in Kodiak Sciences in the second quarter worth $36,000. Sanctuary Advisors LLC bought a new stake in Kodiak Sciences in the second quarter worth $36,000. Headlands Technologies LLC bought a new stake in Kodiak Sciences in the first quarter worth $50,000. Finally, Mirae Asset Global Investments Co. Ltd. bought a new position in Kodiak Sciences during the first quarter valued at $68,000. 89.06% of the stock is currently owned by institutional investors.

Kodiak Sciences Stock Up 4.3 %

Shares of NASDAQ KOD traded up $0.23 during midday trading on Friday, reaching $5.53. 596,873 shares of the stock were exchanged, compared to its average volume of 478,590. The firm has a market cap of $290.96 million, a price-to-earnings ratio of -1.47 and a beta of 2.26. Kodiak Sciences Inc. has a twelve month low of $1.89 and a twelve month high of $7.77. The firm has a 50-day simple moving average of $3.36 and a two-hundred day simple moving average of $3.05.

Kodiak Sciences (NASDAQ:KOD) last announced its quarterly earnings data on Wednesday, August 14th. The company reported ($0.86) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.87) by $0.01. Research analysts expect that Kodiak Sciences Inc. will post -3.52 EPS for the current fiscal year.

Wall Street Analyst Weigh In

A number of research analysts have weighed in on the stock. Barclays boosted their price objective on shares of Kodiak Sciences from $3.00 to $4.00 and gave the company an “underweight” rating in a research report on Friday. HC Wainwright restated a “neutral” rating and issued a $3.00 price target on shares of Kodiak Sciences in a report on Friday. Two research analysts have rated the stock with a sell rating, two have given a hold rating and one has assigned a buy rating to the company’s stock. Based on data from MarketBeat, the company presently has an average rating of “Hold” and an average price target of $5.20.

About Kodiak Sciences

Kodiak Sciences Inc, a clinical stage biopharmaceutical company, researches, develops, and commercializes therapeutics to treat retinal diseases. Its lead product candidate is tarcocimab tedromer (KSI-301), an anti-vascular endothelial growth factor antibody biopolymer that is in Phase IIb/III clinical study to treat wet age-related macular degeneration (AMD), as well as Phase III clinical study for the treatment of diabetic macular edema, naïve macular edema due to retinal vein occlusion, and non-proliferative diabetic retinopathy.